-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-1008 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1008 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: CBP-1008 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-174 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-174 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-174 in Atopic Dermatitis (Atopic Eczema) Drug Details: CBP-174 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Foscenvivint in Adrenocortical Carcinoma (Adrenal Cortex Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Adrenocortical Carcinoma (Adrenal Cortex Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Foscenvivint in Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD19/CD22 CAR-T in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD19/CD22 CAR-T in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CD19/CD22 CAR-T in Mantle Cell Lymphoma Drug Details: Gene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HHCYH-33 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HHCYH-33 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HHCYH-33 in Solid Tumor Drug Details: HHCYH-33 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voruciclib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voruciclib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voruciclib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sitravatinib Malate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sitravatinib Malate in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewQuarterly Processed Snacks pricing trends in the United States
Empower your strategies with our Quarterly Processed Snacks pricing trends in the United States report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inobrodib in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inobrodib in Refractory Multiple Myeloma Drug Details: Inobrodib (CCS-1477) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inobrodib in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inobrodib in Relapsed Multiple Myeloma Drug Details: Inobrodib (CCS-1477) is under...